Ubs Group Ag Point Biopharma Global Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$6.67 - $9.71 $163,168 - $237,535	24,463 Added 38.72%	87,639 $584,000
Q2 2023 Aug 11, 2023	BUY	$6.86 - $10.86 $205,072 - $324,648	29,894 Added 89.82%	63,176 $572,000
Q1 2023 May 12, 2023	SELL	$6.78 - $8.1 $457,480 - $546,547	-67,475 Reduced 66.97%	33,282 $241,000
Q4 2022 Feb 08, 2023	BUY	$5.72 - $9.78 $427,306 - $730,605	74,704 Added 286.74%	100,757 $734,000
Q3 2022 Nov 10, 2022	BUY	$7.24 - $10.31 $106,565 - $151,752	14,719 Added 129.87%	26,053 $201,000
Q2 2022 Aug 10, 2022	BUY	$5.6 - $9.5 $63,470 - $107,673	11,334 New	11,334 $77,000
Q1 2022 May 16, 2022	SELL	$5.46 - $8.13 $13,404 - $19,959	-2,455 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $11,857 - $23,936	2,455 New	2,455 $14,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.